Drug Trial Radar · NCT04478071
Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19)
Last checked: Nov 20, 2026Latest source record: Mar 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
448
Actual
Start
Aug 22, 2020
Primary completion
Mar 7, 2022
Study completion Mar 25, 2022
Sponsor
- Lead sponsor
- The University of Texas Health Science Center, HoustonAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Akebia Therapeutics; United States Department of Defense
- First posted
- Jul 20, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy of vadadustat for the prevention and treatment of acute respiratory distress syndrome (ARDS) in hospitalized patients with Coronavirus Disease 2019 (COVID-19).
Conditions
- Acute Respiratory Distress Syndrome
- Coronavirus Infection
Interventions
vadadustatDrug
Participants will receive vadadustat once daily for 14 days.
placeboDrug
Participants will receive matching placebo once daily for 14 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Who Are Classified 8 (Dead), 7 (Hospitalized, on Invasive Mechanical Ventilation or ECMO), or 6 (Hospitalized, on Non-invasive Ventilation or High Flow Oxygen Devices) on the NIAID Ordinal ScaleTime frame: day 14
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The University of Texas Health Science Center at Houston
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.